Kaletra is an antiretroviral medication approved for the treatment of hiv infection. It contains the protease inhibitors lopinavir and ritonavir formulated in a fixed-dose combination. The drug works by inhibiting the viral aspartyl protease enzyme that hiv uses to process its polyproteins. By blocking this enzyme, Kaletra prevents the formation of mature, infectious virions. This inhibition reduces the viral load in the bloodstream and slows the progression of disease. The lowered viral burden allows the immune system to maintain higher cd4 cell counts and reduces opportunistic complications. The active ingredient pair achieves its effect through the synergistic action of lopinavir as the primary inhibitor and ritonavir as a pharmacokinetic enhancer. Together they provide a sustained antiviral effect that helps control hiv replication over the course of therapy.

Kaletra is a fixed-dose combination antiretroviral medication indicated for the treatment of hiv infection. It combines lopinavir and ritonavir to provide synergistic inhibition of the viral protease enzyme. The protease inhibition prevents the maturation of viral particles, rendering them non-infectious. By blocking this enzymatic step the drug reduces the ability of hiv to replicate within host cells. This action leads to lower viral load levels and helps maintain immune function in patients. The overall pharmacological profile supports its role as an oral antiviral therapy in combination regimens.

Common side effects of Kaletra may include nausea diarrhea and stomach discomfort. Some people also report headache and fatigue while taking the medication. Rare but serious reactions can involve heart rhythm changes and liver function abnormalities. Changes in fat distribution have been observed in some patients during longterm use. Skin rash and itching are possible skinrelated responses to the drug. Elevated blood sugar levels have been noted in certain individuals using Kaletra. Muscle pain or weakness may occur especially when combined with other medications. Patients may experience taste disturbances such as altered taste or metallic sensation.

Kaletra can cause nausea diarrhea and abdominal discomfort. Some users experience changes in taste or a metallic sensation. Elevated cholesterol and triglyceride levels have been reported. Liver function may be affected leading to hepatitis or increased liver enzymes. Rarely skin reactions such as rash or itching can occur. Interaction with other medications may alter drug levels and increase the risk of side effects.